TxCell S.A. | Income Statement

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
Sales/Revenue
17.00
1,327.00
920.00
-
-
Cost of Goods Sold (COGS) incl. D&A
-
-
-
415.00
270.00
Gross Income
-
-
-
415.00
270.00
SG&A Expense
6,975.70
11,244.00
14,574.00
15,229.00
12,464.00
EBIT
7,207.00
10,367.00
13,862.00
15,490.00
12,627.00
Unusual Expense
1.40
-
1,167.00
819.00
262.00
Non Operating Income/Expense
0.70
65.00
685.00
15.00
183.00
Interest Expense
0.10
60.00
17.00
73.00
150.00
Pretax Income
7,207.90
10,304.00
14,320.00
16,364.00
12,856.00
Income Tax
1,756.50
2,035.00
3,023.00
2,794.00
1,945.00
Consolidated Net Income
5,451.30
8,269.00
11,297.00
13,570.00
10,911.00
Net Income
5,451.30
8,269.00
11,297.00
13,570.00
10,911.00
Net Income After Extraordinaries
5,451.30
8,269.00
11,297.00
13,570.00
10,911.00
Net Income Available to Common
5,451.30
8,269.00
11,297.00
13,570.00
10,911.00
EPS (Basic)
0.47
0.76
0.90
1.01
0.52
Basic Shares Outstanding
11,680.50
10,829.40
12,601.80
13,394.80
20,860.50
EPS (Diluted)
0.47
0.69
0.80
1.01
0.52
Diluted Shares Outstanding
11,680.50
12,056.20
14,109.80
13,394.80
20,860.50
EBITDA
6,958.60
9,917.00
13,654.00
15,075.00
12,357.00
Other Operating Expense
-
-
-
154.00
107.00
Non-Operating Interest Income
-
58.00
41.00
3.00
-

About TxCell

View Profile
Address
Les Cardoulines HT1
Valbonne-Sophia Antipolis Rhone-Alpes 06560
France
Employees -
Website http://www.txcell.com/index.php/fr
Updated 09/14/2018
TxCell SA is a biotechnology company. The company engages in the research and development of cellular immunotherapy for chronic inflammatory and autoimmune diseases. Its pipeline consists of Ovasave, col treg, lupus, transplantation and car treg dermatology.